We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2019 to Apr 2024
Diabetes drug maker Amylin Pharmaceuticals Inc. (AMLN) drew four first-round bids valuing the company at $25 to $29 a share, with Pfizer Inc. (PFE) dropping out of the process, Bloomberg News reported Monday on its website, citing people with knowledge of the process.
AstraZeneca Plc (AZN), Sanofi (SNY), Merck & Co. (MRK) and Bristol-Myers Squibb Co. (BMY) submitted offers, with revised offers due by the end of the month and a sale likely in July, two people told Bloomberg.
Representatives for Amylin, Merck, Bristol-Myers, AstraZeneca, Sanofi and Pfizer declined comment to Bloomberg.
Full story at: www.bloomberg.com/news/2012-06-04/amylin-said-to-draw-bids-of-25-to-29-a-share-in-first-round.html
-Dow Jones Newswires; 212-416-2900
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
